Bristol Myers Squibb

BREYANZI

View Prices
  1. Home
    2.  / 
  2. Q Code
    3.  / BREYANZI – Q2054

Manufacturer:

Bristol Myers Squibb

Name:

BREYANZI

HCPCS Code Descriptor:

Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Category:

Q Code

HCPCS:

Q2054

NDC(s):

73153-0900-01

Primary Type:

Oncology

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

BREYANZI is an Oncology drug manufactured by Bristol Myers Squibb and administered via the Intravenous route of administration. The Q Code: Q2054 is aligned to the drug BREYANZI.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

10/1/21

HCPCS Effective Date:

10/1/21

HCPCS Short Description:

Lisocabtagene mara car pos t

Billing and Coding Guide:

Not Found

Patient Assistance:

https://www.celltherapy360.com/patients/